Format

Send to

Choose Destination
J Am Acad Dermatol. 2014 Jan;70(1):168-77. doi: 10.1016/j.jaad.2013.09.020. Epub 2013 Nov 1.

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.

Author information

1
Department of Dermatology, St Luke's-Roosevelt Hospital Center, New York, New York.
2
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
3
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey.
4
Department of Dermatology, Mount Sinai School of Medicine, New York, New York.
5
Oregon Medical Research Center, Portland, Oregon.
6
Department of Dermatology, Baylor College of Medicine, Houston, Texas.
7
Department of Dermatology, St Luke's-Roosevelt Hospital Center, New York, New York. Electronic address: jmw27@columbia.edu.

Abstract

BACKGROUND:

Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD.

OBJECTIVE:

We reviewed the literature to define the impact of common psoriasis therapies on cardiovascular measures and outcomes.

RESULTS:

Phototherapy has no major cardiovascular impact and may reduce levels of proinflammatory cytokines. Acitretin increases serum lipids and triglycerides, but has not been shown to increase cardiovascular risk. Cyclosporine A increases blood pressure, serum triglycerides, and total cholesterol. Methotrexate is associated with a decreased risk of CVD morbidity and mortality. Among the biologics, data for tumor necrosis factor inhibitors suggest an overall reduction in cardiovascular events. Most data on short-term ustekinumab use suggest no effect on major adverse cardiovascular events, however some authorities remain concerned. Nevertheless, ustekinumab use over a 4-year period shows a decrease in major adverse cardiovascular events when compared both with the general US population and with psoriatics in Great Britain.

LIMITATIONS:

Most studies lack the power and randomization of large clinical trials and long-term follow-up periods. In addition, the increased risk of CVD associated with psoriasis itself is a confounding factor.

CONCLUSION:

Some therapies for moderate to severe psoriasis, including methotrexate and tumor necrosis factor inhibitors, may reduce cardiovascular events in psoriatic patients. Ustekinumab appears to be neutral but there may be a long-term benefit. Appropriate patient counseling and selection and clinical follow-up are necessary to maximize safety with these agents. Further long-term study is necessary to quantify the benefits and risks associated with biologic therapies.

KEYWORDS:

CHF; CVD; DM; HTN; IL; MACE; MI; MTX; PUVA; PsA; RA; TNF; TNFi; UV; VEGF; adalimumab; biologic therapies; cardiovascular; cardiovascular disease; congestive heart failure; cyclosporine; diabetes mellitus; etanercept; hypertension; infliximab; interleukin; major adverse cardiovascular events; methotrexate; mycophenolate mofetil; myocardial infarction; psoralen plus ultraviolet A; psoriasis; psoriatic arthritis; rheumatoid arthritis; tumor necrosis factor; tumor necrosis factor inhibitor; ultraviolet; ultraviolet therapy; ustekinumab; vascular endothelial growth factor

PMID:
24184141
DOI:
10.1016/j.jaad.2013.09.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center